SWOG clinical trial number
CTSU/E1411

E1411, An Intergroup Randomized Phase II Four Arm Study In Patients >/= 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB / R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV/ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB / LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV / LR)

Closed
Phase
Abbreviated Title
Randomized Ph. II in Untreated MCL, RB-R/RBV-R/RB-LR/RBV-LR
Activated
06/15/2012
Participants
CTSU

Research committees

Lymphoma

Treatment

Rituximab CC-5013 (Lenalidomide) Bortezomib Bendamustine

Eligibility Criteria Expand/Collapse

SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by phone (888/823-5923) or on the CTSU website (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2022

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

M Smith;O Jegede;P Martin;B Till;S Parekh;D Yang;L Kostakoglu Shields;C Casulo;N Bartlett;P Caimi;T Al Baghdadi;K Maddocks;M Romer;D Inwards;R Lerner;L Wagner;R Little;JW Friedberg;J Leonard;B Kahl ASH Annual Meeting (Dec 10 thru 13, 2022, New Orleans, LA), oral presentation

2021

E1411 Randomized Phase 2 Trial of Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma: Addition of Bortezomib to Front-Line BR Induction does not prolong PFS

MR Smith;O Jegede;P Martin;B Till;S Parekh;D Yang;L Kostakoglu Shields;C Casulo;N Bartlett;P Caimi;T Al Baghdadi;K Maddocks;M Romer;D Inwards;R Lerner;L Wagner;R Little;J Friedberg;J Leonard;B Kahl J Clin Oncol 39, 2021 (suppl 15; abstr 7503) (American Society of Clinical Oncology Annual Meeting 2021, oral)

2019

Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)

M Smith;O Jegede;SS Parekh;C Hanson;F Kuhr;P Martin;B Till;M Crump;JP Leonard;JW Friedberg;B Kahl;T Witzig Blood (2019) 134 (Supplement_1): 751, abst 623; American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase
SWOG Clinical Trial Number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
02/23/2023
Accrual
14%
Open
Phase